



## Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018

October 3, 2018

WALTHAM, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- [Entasis Therapeutics](#) (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2018 taking place October 3 - 7, 2018 in San Francisco, California. The presentation will provide an overview of ETX2514SUL, Entasis'  $\beta$ -lactamase inhibitor, ETX2514, in combination with sulbactam. ETX2514SUL recently completed a Phase 2 study for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults. ETX2514SUL is being developed for the treatment of a variety of serious multidrug-resistant infections caused by *Acinetobacter baumannii*.

Details of the presentation are as follows:

**Oral Presentation:** ETX2514/sulbactam

**Presenter:** Robin Isaacs, M.D.

**Session:** Exploring the Antibiotic Pipeline 2018 Symposium

**Date and Time:** Thursday, October 4, 2018 3:00 PM

**Location:** Room N Hall D

A Phase 3 clinical trial evaluating ETX2514SUL against carbapenem-resistant *A. baumannii* infections will begin in the first quarter of 2019.

### **About ETX2514**

ETX2514 is a potent and broad-spectrum inhibitor of class A, C, and D  $\beta$ -lactamases. ETX2514 restores the *in vitro* activity of multiple  $\beta$ -lactams against Gram-negative, multidrug-resistant (MDR) pathogens. Entasis Therapeutics is initially developing ETX2514SUL, the combination of ETX2514 and sulbactam, for the treatment of severe *A. baumannii* infections. Sulbactam is a generic  $\beta$ -lactam which has intrinsic activity against *A. baumannii* but suffers from widespread  $\beta$ -lactamase-mediated resistance. In preclinical studies, ETX2514 restored sulbactam antibacterial activity against *A. baumannii*. ETX2514 has completed single- and multi-ascending dose Phase 1 trials and a Phase 2 trial, in combination with sulbactam, in cUTI. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track status to ETX2514SUL for the treatment of hospital-acquired and ventilator-acquired bacterial pneumonia and bloodstream infections due to *A. baumannii*.

### **About Entasis**

Entasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae*), ETX0282CPDP (targeting Enterobacteriaceae infections), and Non-Beta-lactam PBP inhibitors or NBPs (targeting Gram-negative infections). [www.entasistx.com](http://www.entasistx.com)

### **Forward-Looking Statements**

This press release includes certain disclosures which contain "forward-looking statements," including, without limitation, statements regarding Entasis' expectations regarding the commencement of trading of its shares on the Nasdaq Global Market, the completion and timing of the closing of the public offering, and the expected amount of gross proceeds from the offering. Forward-looking statements are based on Entasis' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, market conditions, risks and uncertainties related to the satisfaction of customary closing conditions related to, and the completion of, the public offering. Many of these factors are beyond Entasis' control. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Entasis undertakes no duty to update such information except as required under applicable law.

### **Company Contact**

Kyle Dow  
Entasis Therapeutics  
(781) 810-0114  
[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### **Investor Contact**

Chris Brinzey  
Westwicke Partners  
(339) 970-2843  
[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

### **Media Contact**

Kari Watson or Stefanie Tuck  
MacDougall Biomedical Communications  
(781) 235-3060  
[kwatson@machbiocom.com](mailto:kwatson@machbiocom.com) or [stuck@machbiocom.com](mailto:stuck@machbiocom.com)

Source: Entasis Therapeutics Holdings Inc.